What is Expression Systems?
Expression Systems specializes in providing premium insect cell culture media, baculovirus, and related products and services for baculovirus and host cell expression technologists globally. Their comprehensive offerings include cell culture media, biological buffers, reagents, molecular tools, and contract services such as baculovirus titering. The company is dedicated to supporting clients in achieving higher cell growth and improved viral stock consistency, notably through their flagship product, ESF AdvanCD. Expression Systems primarily serves researchers and technologists within the biotechnology and pharmaceutical industries, aiming to advance their expression systems development.
How much funding has Expression Systems raised?
Expression Systems has raised a total of $599K across 2 funding rounds:
Debt
$150K
Debt
$449K
Debt (2020): $150K with participation from PPP
Debt (2021): $449K led by PPP
Key Investors in Expression Systems
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Expression Systems?
The recent major strategic investment signals a period of accelerated growth and potential expansion for Expression Systems. This capital infusion is likely to fuel further research and development, enhance production capabilities, and broaden market reach. The company's focus on critical components for biopharmaceutical development positions it to capitalize on the increasing demand for efficient and reliable expression technologies. Future endeavors may include expanding their product portfolio, forging new strategic partnerships, and solidifying their position as a key supplier in the global life sciences market.
See full Expression Systems company page
